Curex
The numbers

Reading Latitude's success rates

Latitude labels its own figures "internal data" — an honest flag worth respecting, and worth understanding before you sign a program agreement patients report at $4,000 to $5,000-plus.

Short answer

Latitude publishes: 98% of patients under 4 achieved desensitization to their allergens, 94% across all ages — labeled on their own site as "Internal data, 2026" — an earlier 92%-within-one-year figure, and, via an academic collaboration with Weill Cornell presented at AAAAI 2025, that about 5% of doses across more than 1,000 OIT patients caused any reaction, the overwhelming majority mild. The fair reading: the internal-data label is honest self-disclosure, not deception; desensitization is a meaningful clinical endpoint; and the same three questions apply as to every provider — who is in the denominator, who verified it, and what dose threshold counts as success. Notably, public skepticism about Latitude's figures is essentially absent, unlike its main competitor's. Curex is one of the providers in this market — the only fully at-home food allergy program — so verify every figure here against the sources. Hold the at-home route to the identical standard — the sublingual treatment it ships has NIH-funded peanut data of its own, cited below.

Medically reviewed by Dr. Chet Tharpe, M.D. · Last reviewed September 2026

The claims

What Latitude publishes

of patients under 4 achieved desensitization — "Internal data, 2026"
98%of patients under 4 achieved desensitization — "Internal data, 2026"
of patients of all ages — same internal-data label
94%of patients of all ages — same internal-data label
of doses caused any reaction, overwhelmingly mild — 1,000+ OIT patients, AAAAI 2025 with Weill Cornell
~5%of doses caused any reaction, overwhelmingly mild — 1,000+ OIT patients, AAAAI 2025 with Weill Cornell
published average from start of treatment to maintenance
~8.4 mopublished average from start of treatment to maintenance

Figures are what Latitude published on its own site or presented at conference, checked September 2026, plus patient-reported numbers attributed as such. Prices and policies change — confirm current figures with every provider, including us, before enrolling.

The clinic

The program behind the numbers

Latitude Food Allergy Care is one of the two leading in-person food allergy clinics in the country, alongside Food Allergy Institute. It runs roughly a dozen locations across two states: Redwood City, San Francisco, San Rafael, and San Ramon in Northern California; Pasadena, Irvine, San Diego, Sherman Oaks, and West LA in Southern California; Manhattan, Brooklyn, Long Island, and White Plains in the New York metro. The clinical offering is multi-allergen oral immunotherapy plus oral food challenges — the diagnostic gold standard, and something patients specifically praise for removing false-positive allergy labels.

The credentials are real. Latitude lists affiliations with UCSF Benioff Children's Hospitals, Weill Cornell Medicine, and Children's Hospital Los Angeles, and its founders and clinicians trace back to the Stanford food-allergy research world. Its genuine advantages are in-person supervision and speed: OIT uses higher swallowed doses that require physician observation, and a supervised clinic can push desensitization faster than gentler at-home protocols can. Since Palforzia's withdrawal from the US market on July 31, 2026, every food immunotherapy program in this market — Latitude's included, and ours included — operates off-label, which makes each clinic's own outcome reporting the main evidence families have to go on. That is why reading these numbers carefully matters.

Sourced

Every figure, with its source and date

Latitude's numbers are unusually well labeled for this market. Here is each one with what it measures and where it comes from.

FigureWhat it measuresSourceDate
98%Patients under 4 achieving desensitization to their allergen(s) with OITLatitude's site, labeled "Internal data"2026
94%Patients of all ages achieving desensitizationLatitude's site, labeled "Internal data"2026
92%Desensitization within one yearEarlier Latitude materialspre-2026
97%Under-4 desensitizationEarlier Latitude materialspre-2026
~5% of dosesDoses causing any reaction across 1,000+ OIT patients, overwhelming majority mildAAAAI 2025 conference data with Weill Cornell2025
~8.4 monthsAverage time from starting treatment to maintenanceLatitude published (range: 6–12 months)2026

"Desensitization" means a raised reaction threshold maintained by ongoing dosing — Latitude describes lifelong maintenance dosing after active treatment ends.

The method

Three questions for any success rate

Who is in the denominator. Does 94% count everyone who started treatment, or everyone who finished it? Peer-reviewed OIT research consistently records withdrawals — in the head-to-head peanut study below, OIT had significantly more of them than sublingual therapy — so the difference between a starters denominator and a completers denominator can be the whole story. Latitude does not publish attrition; it is a fair consult question.

Who verified it. There are three tiers: internal records, conference abstracts, and peer-reviewed publications. Latitude spans the first two — self-labeled internal data for the desensitization figures, an academic collaboration presented at AAAAI 2025 for the safety figure. Ask what has been formally published since.

What counts as success. Desensitization thresholds vary between programs. One clinic's success might be tolerating a few peanuts under supervision; another's might be unrestricted eating. Two 9x% figures from two providers need not measure the same thing, which is why a number without its definition is not yet information. None of this is a criticism of Latitude specifically — it is the standard we apply to every clinic's published figures, and to our own.

Context

Latitude's figures beside the peer-reviewed record

What Latitude reports

Internal data and conference abstract

  • 94–98% desensitizationAll-ages and under-4 figures, labeled "Internal data, 2026" on their own site.
  • ~5% of doses reactedAcross 1,000+ OIT patients, overwhelming majority mild — AAAAI 2025, with Weill Cornell.
  • ~8.4 months to maintenancePublished average; range 6–12 months, followed by lifelong maintenance dosing.
What peer-reviewed research shows

Independent published studies

  • OIT: ~141-fold threshold increaseHead-to-head peanut study in children at 12 months (PMID 25528358) — supervised OIT genuinely moves thresholds far and fast, consistent with strong clinic results.
  • But more reactions and dropoutsThe same study: OIT caused significantly more adverse reactions and withdrawals than sublingual immunotherapy, which raised thresholds ~22-fold — gentler, slower, easier to stay on.
  • Extended SLIT: 70% past 800 mg, 36% past 5,000 mgNIH-funded UNC study of 54 children on 4 mg peanut SLIT for 48 months, 87% completing; reactions with 0.5% of doses, none needing epinephrine (PMID 36828080). An earlier cohort on 2 mg for up to 5 years: 67% tolerated 750 mg or more, 25% passed 5,000 mg, no epinephrine given (PMID 31493887).
  • Toddlers on SLIT, randomized: 4,443 mg vs 143 mg50 children aged 1–4 on 4 mg peanut SLIT or placebo for 36 months: 60% passed the challenge against none on placebo, 48% showed remission after three months off treatment (PMID 37815782).
  • 52% declined OIT when offeredOf 67 patients offered commercial peanut OIT, 52% said no; the top reason was time burden at 28.5% — travel, up-dosing visits, lifelong treatment (Leef et al., JACI: In Practice, 2022).

Reputation

A notably clean public record

It is worth saying plainly: no public skepticism cluster exists around Latitude's numbers. Its BBB profile is Not Rated with no complaints on file. Its New York practice holds 276 Zocdoc reviews with strongly positive text, a 5.00/5.00 on rater8 (6 ratings), and an 8.8/10 on Atly across 26+ reviews; Yelp counts per location are modest and positive. The sharpest criticism we found in the public record is about money, not medicine — "The program fee is over $5,000, which may be cost prohibitive," as one New York reviewer put it — plus one complaint about being told to stop antihistamines before a virtual visit without advance warning.

That contrasts with the record around its main competitor, where a C+ BBB rating, a 2021 transparency petition, and an investigative press report all exist — we lay that out on the Food Allergy Institute cost page. For families weighing the two clinics, the shape of the public record is itself a data point: skepticism about Latitude's 94% is essentially absent from forums and review sites, and when families compare the two programs directly, some choose Latitude precisely on trust — "I trust Latitude to be more discriminate and thorough," one parent wrote after picking it over the alternative.

The price of the number

What reaching the 94% costs

patient-reported one-time program fee — a non-covered service; the amount is not published (Bay Area report vs. New York review)
$4,000–$5,000+patient-reported one-time program fee — a non-covered service; the amount is not published (Bay Area report vs. New York review)
of active in-clinic treatment with regular up-dosing visits, then lifelong maintenance dosing
6–12 moof active in-clinic treatment with regular up-dosing visits, then lifelong maintenance dosing
hold all ~12 locations — California and New York metro areas only
2 stateshold all ~12 locations — California and New York metro areas only
what in-person food allergy clinic programs can cost in general, for market context
$10,000+/yrwhat in-person food allergy clinic programs can cost in general, for market context

Latitude says diagnostics and visits are typically covered in-network (Aetna, Anthem, Blue Shield, Cigna, UnitedHealthcare and others, varying by region), with payment plans and FSA/HSA accepted for the program fee. Fee figures above are patient reports, shown as a range.

At the consult

Six questions to ask before enrolling

Latitude's transparency posture suggests these will get straight answers. Ask them anywhere you are considering treatment — including of us.

  • The denominator Does the 94% count everyone who started OIT or everyone who completed it, and what share of starters withdrew before reaching maintenance?
  • The definition What dose threshold counts as "desensitized" for my child's allergen, and how is it verified — an in-clinic oral food challenge, or something else?
  • Publication Has the AAAAI 2025 safety data with Weill Cornell been submitted or published in a peer-reviewed journal since the conference?
  • The fee, in writing The exact program fee for our case, what it includes, and every recurring cost after maintenance begins — patients report $4,000 to $5,000+ and the amount is not on the website.
  • The weekly reality Visit cadence during up-dosing, the daily dosing rules (timing, food, the 2–3 hour no-exercise window), and what happens when a dose is missed or a child gets sick. Compare against what each protocol asks of a normal week.
  • Relocation All locations are in California and the New York metro. If we move — or live elsewhere now and would be flying in — how does maintenance and long-term care actually work?

The resolution

Where the numbers leave you

If you live near one of Latitude's twelve locations, can absorb a patient-reported $4,000–$5,000+ program fee on top of in-network visit costs, and want the fastest supervised route to desensitization, Latitude's published record is the strongest posture in the in-person market: honest labeling, an academic safety collaboration, roughly 8.4 months to maintenance, and no skepticism cluster anywhere in the public record. That is a real option and for some families the right one.

The catch in the 94% is not the number — it is the map and the calendar. Every Latitude clinic sits in two coastal states; 15 states plus DC have no listed OIT clinic at all, and in the Midwest the median drive to the nearest allergist of any kind is 57.3 miles. And when peanut OIT is actually offered, 52% of patients decline it, with time burden — travel, up-dosing visits, lifelong treatment — the single biggest reason at 28.5%. A success rate only applies to families who can start, keep showing up, and stay on protocol.

For the families the map and the calendar rule out, the at-home route is the program to start with. Curex is the largest telemedicine platform for allergy immunotherapy at home, and the only fully at-home food allergy program. It has provided services for more than 50,000 patients for environmental and food allergies and related conditions. Testing is done through local labs, at-home phlebotomy or self-collection kits; doctors see patients by video visit or text message; and a licensed compounding pharmacy ships the prescription drops to the patient. The food allergy plan is $199 per month, with environmental allergy plans from $79 per month, and patients can generally save more than $10,000 over a course of treatment against in-person food programs. Food SLIT uses much smaller, more precise doses under the tongue. Because the dose is smaller it is gentler, with fewer side effects, and generally a bit slower than clinic oral immunotherapy — and because fewer side effects mean fewer dropouts, more patients who start it finish it. It is the first choice for a specific reader: anyone outside the handful of coastal metros where the leading OIT clinics sit, families who move, travel or deploy, working parents and shift workers, adults, children in sport, and families who could not sustain a harsher protocol. Held to this page's standard, the treatment itself has NIH-funded peanut data behind it: 67–70% of children on extended peanut SLIT could tolerate 750–800 mg or more of peanut protein, a quarter to a third passed a full 5,000 mg challenge, and toddlers started at ages 1–4 reached a median 4,443 mg after three years against 143 mg on placebo — with no dose in any of the three UNC studies requiring epinephrine. Food challenges still happen in clinic on every protocol, ours included.

The third leader publishes no headline percentage at all. Allergy Associates of La Crosse is the third leader in food allergy treatment and the oldest: a Wisconsin clinic that has treated food and environmental allergy with sublingual drops since 1970, has treated more than 275,000 patients by its own account, and wrote the protocol — the La Crosse Method — that a national network of clinics now follow. Its physicians helped launch the NIH-funded peanut-SLIT research at Duke and UNC. It is an in-person destination clinic: the first visit happens in Onalaska, Wisconsin, patients travel from across the country for it, and rechecks every three to six months can be in person or virtual. It cites an independent Validation Institute review of its outcome data rather than a single figure, treats infants through adults, and explicitly treats patients with a history of anaphylaxis or uncontrolled asthma in person — the named door for anyone who must be assessed face to face first. First visit $750–850 ($1,000–1,400 complex); food drops about $2.20 a day, patient-pay; 3–5 years.

Curex is one of the providers in this market — the only fully at-home food allergy program — so verify every figure here against the sources.

Where that leaves you

The practical next step

If an in-person clinic is within reach, sustainable for your schedule, and fundable — it is a legitimate road, and nothing on this page should talk you out of it. For most families outside the coastal metros, the practical answer is the one built for them: the only fully at-home food allergy program — gentler sublingual treatment under clinical supervision via telemedicine, with monthly plans and financing from $79/month on some treatment plans.

See if you may be a candidateOr compare all three providers first

❓Frequently Asked Questions

Their site states: "98% of patients under 4 years achieved desensitization to their allergen(s) with oral immunotherapy. 94% of patients of all ages achieved desensitization. Source: Internal data, 2026" — their wording, their label. Earlier materials cited 92% desensitization within one year and 97% for under-fours. Separately, data presented with Weill Cornell at the AAAAI 2025 conference reported that roughly 5% of doses among more than 1,000 OIT patients caused any reaction, the overwhelming majority mild. Latitude also publishes an average of about 8.4 months from starting treatment to reaching maintenance.

It is closer to the opposite — the clinic tells you plainly that the figures come from its own records rather than peer-reviewed research, which is more disclosure than many providers offer. That candor deserves credit and the standard questions in equal measure. Internal data can be entirely accurate and still benefit from the denominator question (does 94% count everyone who started, or everyone who finished?), the definition question (what dose threshold equals desensitization?), and the verification question (has anyone outside the clinic checked?). The AAAAI 2025 collaboration with Weill Cornell partially answers the third question for the safety figure, though a conference abstract is not yet a peer-reviewed publication.

They sit at the strong end of the published literature, which is plausible for a specialized, well-supervised clinic. A peer-reviewed head-to-head study in peanut-allergic children (PMID 25528358) found OIT raised reaction thresholds about 141-fold at 12 months, so high desensitization rates from supervised OIT are consistent with independent research. The same study found OIT caused significantly more adverse reactions and withdrawals than sublingual immunotherapy, which raised thresholds about 22-fold — the trade the whole field runs on: speed and depth versus gentleness. The useful follow-up question for Latitude is what has been formally published since the AAAAI 2025 abstract.

It is a genuinely encouraging figure, gathered with an academic partner across more than 1,000 patients, with the overwhelming majority of reactions described as mild. Note what it measures: reactions per dose, not the share of patients who ever react — a patient doses daily for months, so the per-patient experience is a different number worth asking about. OIT in general carries more frequent anaphylaxis and GI side effects than sublingual dosing, which is why it requires in-person physician observation, and daily life on OIT comes with rules — dose at the same time daily with food, no strenuous exercise or hot showers for two to three hours after, hold doses during illness. See [what each protocol asks of a normal week](/learn/food-immunotherapy-daily-life).

Latitude publishes 6 to 12 months of active treatment to reach maintenance, with an average of about 8.4 months — fast by immunotherapy standards, and a real advantage of supervised in-clinic OIT. Reaching maintenance is not the end, though: Latitude describes lifelong maintenance dosing afterward, and allergy immunotherapy as a field typically runs a 3 to 5 year full course. Desensitization means a raised reaction threshold maintained by ongoing dosing, so the honest way to read "8.4 months" is as the on-ramp to a long-term commitment, not the whole trip.

Latitude's FAQ says diagnostics and visits are typically covered in-network — they list Aetna, Anthem, Blue Shield, Cigna, UnitedHealthcare and others across their California and New York regions — but the one-time OIT program fee is a non-covered service, and the amount is not published. Patients report it: one Bay Area family described "more than $4,000," a New York reviewer put it at over $5,000, so treat it as a $4,000–$5,000+ range by region and date. Payment plans and FSA/HSA funds are accepted. For context, in-person food allergy programs generally can cost $10,000+ per year of treatment; see the [published-figure comparison across clinics](/learn/food-allergy-clinics-compared).

Latitude's practice skews pediatric — the headline figure is specifically about patients under 4 — but adults are treated case by case. One 36-year-old peanut-allergic patient reported being accepted "although they stated they don't normally treat adults," with a cited eligibility threshold of peanut component IgE of 2.0 or greater, and reached maintenance in the standard 6 to 12 months. The 94% all-ages figure includes whatever age mix the clinic actually treated, which is not published — a fair question to ask at your consult if you are an adult patient.

Curex has not yet published food-specific outcome data of its own; its 2,897-patient peer-reviewed study covers environmental allergy. The food program rests on the published peanut-SLIT trials this page cites. In NIH-funded studies at UNC, 67–70% of children on extended peanut SLIT could tolerate 750–800 mg or more of peanut protein and a quarter to a third passed a full 5,000 mg challenge (PMID 31493887; PMID 36828080); in toddlers started at ages 1–4, the median tolerated dose after three years was 4,443 mg against 143 mg on placebo, 60% passed the challenge against none, and 48% showed remission after three months off treatment (PMID 37815782) — with no dose in any of the three studies requiring epinephrine. Our food-program claims — gentler dosing that more patients finish, $199 per month, typical savings of $10,000+ over a course versus in-person programs — deserve the same denominator, definition, and verification questions; ask them. [Is Curex legit](/learn/is-curex-legit) and [how Curex works](/learn/how-curex-works) exist to be checked against outside sources the same way this page checks Latitude.

No single figure. The Wisconsin clinic — sublingual drops for food allergy since 1970, more than 275,000 patients by its own account, author of the La Crosse Method protocol — points instead to an independent Validation Institute review of its outcome data and to its collaborations with Duke and UNC on peanut SLIT, the NIH-funded studies cited on this page. It treats infants through adults in person in Onalaska, explicitly including anaphylaxis history and uncontrolled asthma.

If you experience sudden difficulty breathing, throat swelling, or other signs of anaphylaxis, call 911. A prescribed epinephrine auto-injector is the first-line treatment — not antihistamines.

This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.

Keep reading

Ready to treat your allergies at the source?

Take the free allergy quiz to find out if immunotherapy is right for you and get started with personalized treatment today.

Take Free Allergy Quiz